New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 11, 2014
04:55 EDTBAX, BAX, BAX, LH, LH, LH, ACT, ACT, ACT, HUM, HUM, HUM, UNH, UNH, UNH, THOR, THOR, THOR, HSIC, HSIC, HSIC, VRTX, VRTX, VRTX, CNC, CNC, CNC, BSX, BSX, BSX, HNT, HNT, HNTBarclays to hold a conference
Healthcare Conference is being held in Miami, Florida on March 11-13.
News For BAX;BSX;CNC;VRTX;HSIC;THOR;UNH;HUM;ACT;LH;HNT From The Last 14 Days
Check below for free stories on BAX;BSX;CNC;VRTX;HSIC;THOR;UNH;HUM;ACT;LH;HNT the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
August 25, 2014
06:17 EDTTHORThoratec downgraded to Neutral from Overweight at Piper Jaffray
August 24, 2014
21:53 EDTUNHNational Association of Chain Drug Stores to hold an expo
2014 NACDS Total Store Expo to be held in Boston on August 23-25.
August 22, 2014
16:11 EDTACTActavis confirms generic Neupro patent challenge
Subscribe for More Information
August 21, 2014
15:37 EDTBAXNektar: Baxter announces positive results from Phase 3 study of BAX 855
Nektar Therapeutics (NKTR) reports Baxter International (BAX) announced positive results from its Phase 3 pivotal clinical trial of BAX 855, an investigational, extended half-life recombinant factor VIII treatment for hemophilia A based on ADVATE, which met its primary endpoint in reducing annualized bleed rates in the prophylaxis arm compared to the on-demand arm. Top-line results from the prospective, global, multi-center Phase 3 study demonstrated that BAX 855 met its primary endpoint in the control and prevention of bleeding, routine prophylaxis and perioperative management for patients who were 12 years or older. Patients in a twice-weekly prophylaxis arm experienced a 95 percent reduction in median ABR as compared to those in the on-demand arm (1.9 vs. 41.5, respectively). BAX 855 was also effective in treating bleeding episodes, 96 percent of which were controlled with one or two infusions. The half-life of BAX 855 was 1.4 - 1.5 times that of ADVATE, consistent with the findings from the Phase 1 study. No patients developed inhibitors to BAX 855 and no treatment-related serious adverse events, including hypersensitivity, were reported. The most common product-related adverse event was headache. Baxter expects to submit a Biologics License Application for BAX 855 to the U.S. Food and Drug Administration before the end of 2014 and will present additional data in the coming months. In addition to an ongoing continuation study for patients who have completed the pivotal trial, the company is initiating a Phase 3, prospective, open-label, multi-center study to evaluate the safety and efficacy of BAX 855 among 60 previously treated patients under the age of 12 with severe hemophilia A. Consistent with guidelines published by the European Medicines Agency that require a study in children less than 12 years of age prior to filing, Baxter expects to file a Marketing Authorization Application with the EMA upon the completion of the pediatric study
15:16 EDTACTDEA restricts painkiller drug prescriptions to curb abuse, WSJ reports
The Drug Enforcement Agency, or DEA, will reclassify hydrocodone combination painkiller drugs and place them in the category of medical substances that have the highest potential for harm in an attempt to curb the widespread abuse of the drugs, according to The Wall Street Journal. The rescheduling of the drugs will take effect in 45 days and result in people being able to obtain the drug for only 90 days without obtaining a new prescription. Major manufacturers of these drugs include Teva Pharmaceutical (TEVA), Mallinckrodt (MNK), AbbVie (ABBV), and Actavis (ACT). Reference Link
09:02 EDTBAXBaxter announces BAX 855 met primary endpoint in Phase 3 study
Baxter announced "positive" results from its Phase 3 pivotal clinical trial of BAX 855, which met its primary endpoint in reducing annualized bleed rates in the prophylaxis arm compared to the on-demand arm. Top-line results from the prospective, global, multi-center Phase 3 study demonstrated that BAX 855 met its primary endpoint in the control and prevention of bleeding, routine prophylaxis and perioperative management for patients who were 12 years or older. Patients in a twice-weekly prophylaxis arm experienced a 95% reduction in median ABR as compared to those in the on-demand arm. BAX 855 was also effective in treating bleeding episodes, 96% of which were controlled with one or two infusions. The half-life of BAX 855 was 1.4 Ė 1.5 times that of ADVATE, consistent with the findings from the Phase 1 study. No patients developed inhibitors to BAX 855 and no treatment-related serious adverse events, including hypersensitivity, were reported. The most common product-related adverse event was headache. Baxter expects to submit a Biologics License Application for BAX 855 to the U.S. Food and Drug Administration before the end of 2014 and will present additional data in the coming months. In addition to an ongoing continuation study for patients who have completed the pivotal trial, the company is initiating a Phase 3, prospective, open-label, multi-center study to evaluate the safety and efficacy of BAX 855 among 60 previously treated patients under the age of 12 with severe hemophilia A. Consistent with guidelines published by the European Medicines Agency that require a study in children less than 12 years of age prior to filing, Baxter expects to file a Marketing Authorization Application with the EMA upon the completion of the pediatric study.
07:55 EDTACTActavis volatility expected to move on Pfizer considering new target report
Actavis (ACT) volatility is expected to move on Pfizer (PFE) considering other overseas alternatives, Bloomberg reports. Overall option implied volatility of 27 is near its 26-week average of 31 according to Track Data, suggesting decreasing price movement.
07:47 EDTACTPfizer looking at new targets, including Actavis, Bloomberg reports
While it weighs another attempt to acquire AstraZeneca (AZN), Pfizer is considering other overseas alternatives, including Actavis (ACT), Bloomberg reports, citing people familiar with the matter. Pfizer prefers to reach a deal with AstraZeneca, and a move on another company is unlikely "anytime soon," Bloomberg adds, citing its sources. Shares of Actavis are rising 3%, or $6.65, to $230.01 in pre-market trading, while AstraZeneca is up 2% to $72.59. Reference Link
07:38 EDTACTSupernus announces paragraph IV Abbreviated NDA filing for Trokendi XR
Subscribe for More Information
August 20, 2014
08:31 EDTHNTCognizant deal with Health Net has encouraging read through, says Cowen
Cowen noted Cognizant (CTSH) shareholders were concerned over its deal with Health Net (HNT) but noted management feels the deal is a true partnership. The firm feels management's positive comments are encouraging and address the execution and profitability concerns of shareholders. Shares of Cognizant are Outperform rated with a $50 price target.
August 19, 2014
16:33 EDTBAXBaxter to expand Alabama facility to increase dialyzers production
Subscribe for More Information
11:32 EDTLHLabCorp prenatal test a negative for Sequenom, says Maxim
Maxim views LabCorp's (LH) announcement today that it will begin offering the informaSeq prenatal test as a long-term negative for Sequenom (SQNM) due to increased competition. The news is also negative for Illumina (ILMN) and PerkinElmer (PKI), who both offer Non-Invasive Prenatal Tests, Maxim adds. The firm recommends buying shares of LabCorp and keeps a Buy rating on the name with a $130 price target.
11:18 EDTACTDepomed announces favorable ruling in Gralise case
Subscribe for More Information
10:32 EDTACTDepomed higher after favorable ruling in Gralise case
Subscribe for More Information
08:47 EDTLHLabCorp announces availability of InformaSeq non-invasive prenatal test
Laboratory Corporation of America Holdings announced the availability of the informaSeq Prenatal Test. The informaSeq Prenatal Test is an advanced, non-invasive, next-generation prenatal screening assay that can assess risk for multiple fetal chromosomal aneuploidies, or abnormalities in the number of chromosomes, from a single maternal blood draw. There are testing options for several additional common sex-related aneuploidies. The test is offered through Integrated Genetics, part of the LabCorp Specialty Testing Group of laboratories that offer advanced esoteric and genomic testing.
08:32 EDTHNTHealth Net says CFO Joseph Capezza to retire
Health Net announced that James Woys has been named executive vice president, chief financial and operating officer, and interim treasurer, effective September 2. This is a new position. Woys has been executive vice president and COO since November 2007. Previously Woys served as acting CFO from November 2006 through October 2007. The company announced that Joseph C. Capezza, currently executive vice president, CFO and treasurer, will retire as CFO. He will have a consulting contract with the company through year end to assist with transition issues. Capezza has been Health Netís CFO since November 2007.
07:26 EDTACTActavis confirms positive results from RECLAIM pivotal Phase III studies
Subscribe for More Information
05:14 EDTBSXBoston Scientific, ASAHI INTECC announce joint development programs
Subscribe for More Information
August 18, 2014
10:06 EDTACTLannett surges after upbeat Q4, FY14 outlook
Subscribe for More Information
09:00 EDTHNTHealth Net fundamentals remain favorable, says Susquehanna
Susquehanna said Health Net (HNT) fundamentals remain favorable following meetings with management. The firm cited the company's conservative outlook and the benefit of its back office contract with Cognizant (CTSH) which positions the company well for sustainable earnings growth through 2016. Shares of Health Net remain Positive rated with a $55 price target on the shares.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use